Attached files
| file | filename |
|---|---|
| EX-99.2 - EX-99.2 - MARINUS PHARMACEUTICALS INC | a16-14156_1ex99d2.htm |
| EX-99.1 - EX-99.1 - MARINUS PHARMACEUTICALS INC | a16-14156_1ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported)
June 28, 2016
MARINUS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-36576 |
|
20-0198082 |
|
(State or other jurisdiction |
|
(Commission File Number) |
|
(I.R.S. Employer |
|
170 N. Radnor Chester Rd, Suite 250 |
|
19087 |
|
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (484) 801-4670
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On June 28, 2016, Marinus Pharmaceuticals, Inc. (the “Company”) issued a press release announcing top-line results from a Phase 2 exploratory clinical trial with ganaxolone in Fragile X Syndrome. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K. On June 28, 2016, the Company conducted an investor conference call and webcast to discuss the results of this trial. A copy of the slides presented during that call is filed as Exhibit 99.2 to this Current Report on Form 8-K
Item 9.01. Financial Statements and Exhibits.
|
(d) |
Exhibits |
|
Exhibit |
|
Description |
|
|
|
|
|
99.1 |
|
Press Release, dated June 28, 2016, of Marinus Pharmaceuticals, Inc. |
|
|
|
|
|
99.2 |
|
Slide Presentation at Investor Conference Call and Webcast on June 28, 2016 at 9:00 a.m. ET. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
MARINUS PHARMACEUTICALS, INC. | |
|
|
| |
|
|
|
|
|
|
By: |
/s/ Edward Smith |
|
|
|
Edward Smith, |
|
|
|
Vice President, Chief Financial Officer, |
|
|
|
Secretary and Treasurer |
Date: June 28, 2016